Nasdaq · Healthcare
TELA Bio, Inc. (TELA)
As-reported financials and recent SEC filings for TELA Bio, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$80.3M
Net income
$-38.8M
Net margin
-48.4%
Diluted EPS
$-0.83
ROE
-615.1%
P/E (TTM)
—
Market cap
—
Debt / equity
8.8×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $80.3M | $69.3M | $58.5M | $41.4M | $29.5M |
| Gross profit | — | — | — | — | — |
| Operating income | $-33.8M | $-34.1M | $-44.1M | $-39.0M | $-29.5M |
| Net income | $-38.8M | $-37.8M | $-46.7M | $-44.3M | $-33.3M |
| Diluted EPS | $-0.83 | $-1.33 | $-2.04 | $-2.72 | $-2.30 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →32026-06-11
View on EDGAR →32026-06-11
View on EDGAR →42026-06-11
View on EDGAR →32026-06-11
View on EDGAR →42026-06-11
View on EDGAR →Largest Healthcare peers
Go deeper on TELA
Search TELA Bio, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.